CN109527313A - 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 - Google Patents
一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 Download PDFInfo
- Publication number
- CN109527313A CN109527313A CN201811554191.0A CN201811554191A CN109527313A CN 109527313 A CN109527313 A CN 109527313A CN 201811554191 A CN201811554191 A CN 201811554191A CN 109527313 A CN109527313 A CN 109527313A
- Authority
- CN
- China
- Prior art keywords
- parts
- acid
- relieved
- vision
- physical fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004438 eyesight Effects 0.000 title claims abstract description 46
- 235000020510 functional beverage Nutrition 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 150000001413 amino acids Chemical class 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 21
- 229940088594 vitamin Drugs 0.000 claims abstract description 20
- 229930003231 vitamin Natural products 0.000 claims abstract description 20
- 235000013343 vitamin Nutrition 0.000 claims abstract description 20
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 18
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 15
- 239000002773 nucleotide Substances 0.000 claims abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 13
- 235000010755 mineral Nutrition 0.000 claims abstract description 13
- 239000011707 mineral Substances 0.000 claims abstract description 13
- 239000005018 casein Substances 0.000 claims abstract description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000021240 caseins Nutrition 0.000 claims abstract description 11
- 229930014669 anthocyanidin Natural products 0.000 claims abstract description 10
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims abstract description 10
- 235000008758 anthocyanidins Nutrition 0.000 claims abstract description 10
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 9
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 9
- 229960000367 inositol Drugs 0.000 claims abstract description 9
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims abstract description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 8
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 8
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 8
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 8
- 229960001948 caffeine Drugs 0.000 claims abstract description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 8
- 239000011746 zinc citrate Substances 0.000 claims abstract description 8
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 8
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 8
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 7
- 239000012141 concentrate Substances 0.000 claims abstract description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 7
- 229940105902 mint extract Drugs 0.000 claims abstract description 7
- 235000021119 whey protein Nutrition 0.000 claims abstract description 7
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 6
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 6
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 55
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 46
- 239000002994 raw material Substances 0.000 claims description 38
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 24
- 238000012216 screening Methods 0.000 claims description 23
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 15
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 229960003512 nicotinic acid Drugs 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 235000001968 nicotinic acid Nutrition 0.000 claims description 13
- 239000011664 nicotinic acid Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 235000002639 sodium chloride Nutrition 0.000 claims description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 12
- 229940055726 pantothenic acid Drugs 0.000 claims description 12
- 235000019161 pantothenic acid Nutrition 0.000 claims description 12
- 239000011713 pantothenic acid Substances 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 11
- 108010076119 Caseins Proteins 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 235000012680 lutein Nutrition 0.000 claims description 10
- 229960005375 lutein Drugs 0.000 claims description 10
- 239000001656 lutein Substances 0.000 claims description 10
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 10
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 10
- 102000016938 Catalase Human genes 0.000 claims description 9
- 108010053835 Catalase Proteins 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 9
- 239000001506 calcium phosphate Substances 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 9
- 229940107700 pyruvic acid Drugs 0.000 claims description 9
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 9
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 9
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 9
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 8
- 229960003624 creatine Drugs 0.000 claims description 8
- 239000006046 creatine Substances 0.000 claims description 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229960002477 riboflavin Drugs 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- 235000005979 Citrus limon Nutrition 0.000 claims description 7
- 244000131522 Citrus pyriformis Species 0.000 claims description 7
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 7
- 235000000638 D-biotin Nutrition 0.000 claims description 7
- 239000011665 D-biotin Substances 0.000 claims description 7
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 7
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 7
- 108010079058 casein hydrolysate Proteins 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 7
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 claims description 7
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 7
- 235000010350 erythorbic acid Nutrition 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 229940099596 manganese sulfate Drugs 0.000 claims description 7
- 239000011702 manganese sulphate Substances 0.000 claims description 7
- 235000007079 manganese sulphate Nutrition 0.000 claims description 7
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 7
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- DINKXUCRJBUQAZ-UHFFFAOYSA-N tert-butyl 5-bromopyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CN=CC(Br)=C1 DINKXUCRJBUQAZ-UHFFFAOYSA-N 0.000 claims description 7
- 229940026510 theanine Drugs 0.000 claims description 7
- 229960000984 tocofersolan Drugs 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 6
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 6
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 6
- 239000011706 ferric diphosphate Substances 0.000 claims description 6
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 6
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 6
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 150000002739 metals Chemical class 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 6
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 6
- 229960005055 sodium ascorbate Drugs 0.000 claims description 6
- 239000011781 sodium selenite Substances 0.000 claims description 6
- 235000015921 sodium selenite Nutrition 0.000 claims description 6
- 229960001471 sodium selenite Drugs 0.000 claims description 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 6
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 6
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 6
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 6
- 229940061671 uridine 5-mo-phos disod Drugs 0.000 claims description 6
- 235000005282 vitamin D3 Nutrition 0.000 claims description 6
- 239000011647 vitamin D3 Substances 0.000 claims description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 6
- 229940021056 vitamin d3 Drugs 0.000 claims description 6
- 229930010555 Inosine Natural products 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 4
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 4
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 3
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 235000013928 guanylic acid Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 5
- 206010016256 fatigue Diseases 0.000 description 45
- 235000013305 food Nutrition 0.000 description 31
- 235000013361 beverage Nutrition 0.000 description 22
- 230000006870 function Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000004060 metabolic process Effects 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- -1 iron ion Chemical class 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000003860 sleep quality Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000005374 Poisoning Diseases 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 231100000572 poisoning Toxicity 0.000 description 7
- 230000000607 poisoning effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 208000003464 asthenopia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960000342 retinol acetate Drugs 0.000 description 3
- 235000019173 retinyl acetate Nutrition 0.000 description 3
- 239000011770 retinyl acetate Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 229940046001 vitamin b complex Drugs 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000007287 cheilitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- WNCAVNGLACHSRZ-KAMYIIQDSA-N Allithiamine Chemical compound C=CCSSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-KAMYIIQDSA-N 0.000 description 1
- WNCAVNGLACHSRZ-UHFFFAOYSA-N Allithiamine Natural products C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-UHFFFAOYSA-N 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical group [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 239000005955 Ferric phosphate Substances 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SLIUELDPAPMQIB-IDIVVRGQSA-N [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 Chemical compound [Na].[Na].[C@@H]1([C@H](O)[C@H](O)[C@@H](COP(=O)(O)O)O1)N1C=NC=2C(O)=NC=NC12 SLIUELDPAPMQIB-IDIVVRGQSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000005471 carotenols Nutrition 0.000 description 1
- 150000001748 carotenols Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000013890 disodium inosinate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000008496 endemic goiter Diseases 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940032958 ferric phosphate Drugs 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019261 food antioxidant Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000036734 inhibitory postsynaptic potential Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000011499 joint compound Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910001511 metal iodide Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 235000008373 pickled product Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 239000011819 refractory material Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000021468 vitamin B8 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种可缓解视觉和体力疲劳的功能性饮料,包括枸杞提取物7‑15、薄荷提取物3‑4、山茱萸提取物1‑5、茶树紫芽花青素10‑17、乳糖75‑125、浓缩乳清蛋白32‑55、咖啡因0.08‑0.12、低聚半乳糖14‑26、玛咖0.2‑1.5、肌醇19‑20、柠檬酸锌0.04‑0.05、酪蛋白磷酸肽2‑3、β‑环状糊精0.01‑0.02、调节剂0.3‑0.56、抗氧化剂0.25‑0.58、氨基酸4‑7.2、核苷酸0.25‑0.4、维生素组合物1.562‑3.155、矿物质0.32‑0.485和水1500‑4500。有益效果:能够有效缓解疲劳,促进体力恢复。
Description
技术领域
本发明涉及食品加工技术领域,具体来说,涉及一种可缓解视觉和体力疲劳的功能性饮料及其制备方法。
背景技术
当人们进行大强度的运动时,会丢失一些汗水,汗水中主要成份是水,但还含有少量的电解质,主要是钠和氯离子,还有少量的钾和钙,身体中的电解质就是在这时悄悄流失的。就常会出现全身乏力、视力疲劳、注意力不集中等情况,从而影响人们的工作效率。体力疲劳是由于当人持续长时间、大强度的体力活动运动时,体内产生了大量的代谢物,另外,视觉疲劳很多时候都由于眼睛干涩、头疼、头晕都无法工作。
目前市场上销售的功能饮料,这些功能性饮料以快速恢复体力为主,但其大多额外添加了大量的糖分,人体长期饮用或过量饮用上述饮料后不仅会摄入大量非必需元素且容易引发肥胖问题。如何使得功能性饮料兼具可快速缓解体力和视力疲劳亦可作为长期保健饮料饮用,成为行业的发展方向。
针对相关技术中的问题,目前尚未提出有效的解决方案。
发明内容
针对相关技术中的问题,本发明提出一种可缓解视觉和体力疲劳的功能性饮料及其制备方法,以克服现有相关技术所存在的上述技术问题。
为此,本发明采用的具体技术方案如下:
根据本发明的一个方面,提供了一种可缓解视觉和体力疲劳的功能性饮料。
该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物7-15份、薄荷提取物3-4份、山茱萸提取物1-5份、茶树紫芽花青素10-17份、乳糖75-125份、浓缩乳清蛋白32-55份、咖啡因0.08-0.12份、低聚半乳糖14-26份、玛咖0.2-1.5份、肌醇19-20份、亚油酸2.8-2.86份、柠檬酸0.1-0.5份、香精0.1-0.2份、α-亚麻酸0.38-0.39份、柠檬酸钠0.1-0.3份、苯甲酸钠0.1-0.3份、水解酪蛋白17.5-18.5份、柠檬黄0.1-0.2份、二十二碳六烯酸10-30份、柠檬酸锌0.04-0.05份、酪蛋白磷酸肽2-3份、卵磷脂25-35份、β-环状糊精0.01-0.02份、调节剂0.3-0.56份、抗氧化剂0.25-0.58份、氨基酸4-7.2份、核苷酸0.25-0.4份、维生素组合物1.562-3.155份、矿物质0.32-0.485份和水1500-4500份。
进一步的,所述调节剂包括以下原料组份:三聚磷酸钠0.05-0.08份、一水柠檬酸0.2-0.4份和藻酸丙二醇酯0.05-0.08份。
进一步的,所述抗氧化剂包括以下原料组份:叶黄素0.05-0.25份、D-异抗坏血酸钠0.15-0.22份、超氧化物歧化酶0.02-0.04份、过氧化氢酶0.01-0.03份和丙酮酸0.02-0.04份。
进一步的,所述氨基酸包括以下原料组份:牛磺酸1-1.2份、肌酸0.4-1.2份、亮氨酸0.4-0.8份、甘氨酸0.3-0.6份、左旋肉碱0.4-0.8份、酪氨酸0.2-0.4份、赖氨酸0.6-0.8份、天冬氨酸0.3-0.6份、茶氨酸0.2-0.4份和谷氨酰胺0.2-0.4份。
进一步的,所述核苷酸包括以下原料组份:5’单磷酸腺苷0.05-0.08份、5’肌苷酸二钠0.05-0.08份、5’鸟苷酸二钠0.05-0.08份、5’尿苷酸二钠0.05-0.08份和5’胞苷酸二钠0.05-0.08份。
进一步的,所述维生素组合物包括以下原料组份:氯化胆碱0.015-0.025份、L抗坏血酸钠0.055-0.085份、醋酸视黄酯0.015-0.025份、D泛酸钙0.025-0.035份、dl-α-生育酚0.025-0.045份、胆钙化醇0.035-0.045份、植物甲萘醌0.025-0.045份和B族组合物1.367-2.85份。
进一步的,所述B族组合物包括以下原料组份:核黄素0.065-0.095份、烟酰胺0.025-0.085份、D-生物素0.012-0.025份、叶酸0.015-0.025份、烟酸0.045-0.065份、泛酸1.1-2.4份、盐酸硫胺素0.045-0.065份、盐酸吡哆醇0.035-0.045份和钴胺素0.025-0.045份。
进一步的,所述矿物质包括以下原料组份:磷酸氢钙0.02-0.025份、磷酸三钙0.02-0.03份、氯化镁0.06-0.08份、焦磷酸铁0.065-0.095份、氧化锌0.035-0.065份、氯化钠0.015-0.025份、氯化钾0.045-0.065份、碘化钾0.04-0.06份、硫酸锰0.01-0.02份和亚硒酸钠0.01-0.02份。
根据本发明的另一方面,提供了一种可缓解视觉和体力疲劳的功能性饮料的制备方法。
该可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
通过预先配置的低频共振仪对所述水进行处理备用;
按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
将制得的所述功能饮料成品密封灌装。
进一步的,所述灭菌处理采用高温杀菌,其温度为100-110℃,杀菌时间为30-35分种。
其中,本发明所采用的原料组份阐述如下:
枸杞:枸杞多糖是一种水溶性多糖,是枸杞中最主要的活性成分,研究表明枸杞多糖具有促进免疫、抗衰老、抗肿瘤、清除自由基、抗疲劳、抗辐射、保肝、生殖功能保护和改善等作用。
薄荷:薄荷是中国常用中药,幼嫩茎尖可作菜食,全草又可入药,治感冒发热喉痛,头痛,目赤痛,肌肉疼痛,皮肤风疹搔痒,麻疹不透等症,此外对痈、疽、疥、癣、漆疮亦有效。
山茱萸:含有生理活性较强的皂甙原糖、多糖、苹果酸、酒石酸、酚类、树脂、鞣质等成分。其味酸涩,具有滋补、健胃、利尿、补肝肾,益气血等功效。
茶树紫芽花青素:花青素是一种强有力的抗氧化剂,它能够保护人体免受一种叫做自由基的有害物质的损伤。与其它抗氧化剂不同,花青素有跨越血脑屏障的能力,可以直接保护大脑中枢神经系统。花青素还能够增强血管弹性,改善循环系统和增进皮肤的光滑度,抑制炎症和过敏,改善关节的柔韧性。
通过防止应激反应和吸烟引起的血小板凝集来减少心脏病和中风的发生;增强免疫系统能力来抵御致癌物质;具有抗炎功效,因而可以预防包括关节炎和肿胀在内的炎症;增强动脉、静脉和毛细血管弹性;保护动脉血管内壁;保持血细胞正常的柔韧性从而帮助血红细胞通过细小的毛细血管,因此增强了全身的血液循环、为身体各个部分的器官和系统带来直接的益处,并增强细胞活力;松弛血管从而促进血流和防上高血压;防止肾脏释放出的血管紧张素转化酶所造成的血压升高;通过对弹性蛋白酶和胶原蛋白酶的抑制使皮肤变得光滑而富有弹性,从内部和外部同时防止由于过度日晒所导致的皮肤损伤等等。
乳糖:作为粉状食品色素的吸附分散剂,降低色素浓度,便于使用并降低贮藏期间的变色,利用易压缩成形和吸水性低的特点,作压片等赋形剂。
浓缩乳清蛋白:采用超滤技术浓缩乳清中蛋白质,然后干燥制得可溶性粉末,广泛用于食品加工业。
咖啡因:直接作用于中枢神经,促使思维变得敏捷清晰;能减少疲劳;能促进代谢;能刺激肝脏释放肝糖原以增加体内能量;促使血液中肾上腺素明显增加,从而加快心率,增加血流量,提高氧输送能力,促使三羧酸循环得以顺利进行,保证能量不断得到补充。
低聚半乳糖:低聚半乳糖是人体肠道中双歧杆菌、嗜酸乳酸杆菌等有益菌极好的营养源和有效的增殖因子,可以改善人体肠道的消化吸收功能,促进肠道蠕动,减轻可能的上火症状,提升肠道健康,促进益生菌生长,促进钙质吸收。
玛咖:富含高单位营养素,对人体有滋补强身的功用。
肌醇:肌醇广泛分布在动物和植物体内,是动物、微生物的生长因子,和胆碱共同对人体大脑记忆区的神经元及神经突触的形成起关键作用。
亚油酸:由于具有降低人体血液中胆固醇和血脂的作用,可作为治疗动脉粥样硬化药物的原料。
柠檬酸:因为柠檬酸有温和爽快的酸味,普遍用于各种饮料、汽水、葡萄酒、糖果、点心、饼干、罐头果汁、乳制品等食品的制造。柠檬酸的盐类如柠檬酸钙和柠檬酸铁是某些食品中需要添加钙离子和铁离子的强化剂。柠檬酸的酯类如柠檬酸三乙酯可作无毒增塑剂,制造食品包装用塑料薄膜,是饮料和食品行业的酸味剂,防腐剂。
香精:一定香气的原料,它是制造过程中的关键原料之一。
α-亚麻酸:α-亚麻酸是构成细胞膜和生物酶的基础物质,对人体健康起决定性作用,α-亚麻酸是人体健康必需却又普遍缺乏,急需补充的一种必需营养素。
柠檬酸钠:在食品、饮料工业中用作酸度调节剂、风味剂、稳定剂。
苯甲酸钠:苯甲酸钠属于酸性防腐剂在酸性环境下防腐效果较好,是很常用的食品防腐剂,有防止变质发酸、延长保质期的效果,在世界各国均被广泛使用。
水解酪蛋白:是哺乳动物包括母牛、羊和人奶中的主要蛋白质,又称干酪素、酪朊、乳酪素。
柠檬黄:为水溶性合成色素。呈鲜艳的嫩黄色,是单色品种。多用于食品、饮料、药品、化妆品、饲料、烟草、玩具、食品包装材料等的着色,也用于羊毛、蚕丝的染色及制造色淀。
二十二碳六烯酸:俗称脑黄金,是一种对人体非常重要的不饱和脂肪酸,DHA是神经系统细胞生长及维持的一种主要成分,是大脑和视网膜的重要构成成分。
柠檬酸锌:主要用于食品、固体饮料、乳制品、婴幼儿食品、食盐、牙膏、保健品等。
酪蛋白磷酸肽:促进小肠对钙的吸收,促进骨骼对钙的利用,促进牙齿对钙的利用。
卵磷脂:使大脑神经及时得到营养补充,有利于消除疲劳,缓解神经紧张。
β-环状糊精:作为稳定剂、加工助剂等。
三聚磷酸钠:常用于食品中,作水分保持剂、品质改良剂、PH调节剂、金属螯合剂。
一水柠檬酸:主要用于食品、饮料行业作为酸味剂、调味剂及防腐剂、保鲜剂。
藻酸丙二醇酯:常做为饮料产品的增稠、稳定、乳化剂使用。
叶黄素:天然叶黄素是一种优良的抗氧化剂,能抵御游离基在人体内造成细胞与器官损伤,从而可防止机体衰老引发的心血管硬化、冠心病和肿瘤病等。叶黄素和玉米黄质是眼睛中仅有的2种类胡萝卜素,预防老年性眼球视网膜黄斑区病变引起的视力下降与失明是叶黄素的独特功能。
D-异抗坏血酸钠:是一种新型生物型食品抗氧、防腐保鲜助色剂。能防止腌制品中致癌物质-亚硝胺的形成,根除食品饮料的变色、异味和混浊等不良现象。
超氧化物歧化酶:一种源于生命体的活性物质,能消除生物体在新陈代谢过程中产生的有害物质,对人体不断地补充SOD具有抗衰老的特殊效果。
过氧化氢酶:过氧化氢酶在食品工业中被用于除去用于制造奶酪的牛奶中的过氧化氢,过氧化氢酶也被用于食品包装,防止食物被氧化。
丙酮酸:丙酮酸可通过乙酰COA和三羧酸循环实现体内糖、脂肪和氨基酸间的互相转化,因此,丙酮酸在三大营养物质的代谢联系中起着重要的枢纽作用。
牛磺酸:提高机体对蛋白质的利用率,促进大脑细胞结构和功能的发育,牛磺酸直接参加神经细胞大分子合成代谢,促进大脑神经细胞增殖、分化,对婴幼儿大脑发育、神经传导、视觉机能的完善、钙的吸收有良好作用。
肌酸:补充肌酸可以有效的提高肌力、速度和耐力。提高体能和训练水平,防止疲劳。
亮氨酸:亮氨酸的作用包括与异亮氨酸和缬氨酸一起合作修复肌肉,控制血糖,并给身体组织提供能量。亮氨酸,异亮氨酸和缬氨酸都是支链氨基酸,它们有助于促进训练后的肌肉恢复。其中亮氨酸是最有效的一种支链氨基酸,可以有效防止肌肉损失,因为它能够更快的分解转化为葡萄糖。
甘氨酸:在中枢神经系统,尤其是在脊椎里,甘氨酸是一个抑制性神经递质。假如甘氨酸接受器被激活,氯离子通过离子接受器进入神经细胞导致抑制性突触后电位。
左旋肉碱:协助婴儿维持正常体温,保证源于脂肪的能量供应,预防婴儿肉碱缺乏症。
酪氨酸:氨基酸输液及氨基酸复合制剂的原料,作营养增补剂。用于治疗脊髓灰质炎和结核性脑炎/甲状腺机能亢进等症。
赖氨酸:属于蛋白质的重要组成部分和人体必需氨基酸之一,可以调节人体代谢平衡;能提高钙的吸收以及在体内的积累,加速骨胳生长;有促进生长发育、增加食欲、减少疾病和增强体质的作用。
天冬氨酸:氨基酸输液、钾、钙等无机离子补充剂、疲劳恢复剂、氨解毒剂、临床诊断药;治疗慢性肝炎、心肌代谢障碍、低钾、或缺血性贫血;新型甜味剂天冬甜素的原料;营养增补剂,添加于各种清凉饮料。
茶氨酸:具有催眠,又可以解消疲劳、降低血压和提高学习记忆能力。
谷氨酰胺:及时适量地补充谷氨酰胺能有效地防止肌肉蛋白的分解,并可通过细胞的水合作用,增加细胞的体积,促进肌肉增长。谷氨酰胺还是少数几种能促进生长激素释放的氨基酸之一。研究表明,口服2克谷氨酰胺就能使生长激素的水平提高4倍,使胰岛素和睾酮分泌增加,从而增强肌肉的合成作用。
5’-单磷酸腺苷:又名一磷腺苷酸,一种在核糖核酸中发现的核苷酸,是一种磷酸及核苷腺苷的酯,并由磷酸盐官能团、戊糖核酸糖及碱基腺嘌呤所组成,也是维生素B8,一种水溶性维生素。
5’-肌苷酸二钠:是无色至白色结晶,或白色结晶性粉末,以保护其不受鱼肉等食品中磷酸酯酶的分解并使其发挥最大的呈味力。
5’-鸟苷酸二钠:是无色至白色结晶,或白色结晶性粉末,鲜味强度为肌苷酸钠的2.3倍,与谷氨酸钠并用有很强的协同作用,不吸湿,溶于水,水溶液稳定。
5’-尿苷酸二钠:为白色或类白色粉末,可作为生产核酸类药物中间体,保健食品及生化试剂。
5’-胞苷酸二钠:调味剂,亦用于补充牛乳中的核苷酸,以生产接近人乳的母乳化牛奶,能增强婴儿对细菌性疾病的抵抗能力。
氯化胆碱:可预防肝脏、肾脏中的脂肪积累及其组织变性;可促进氨基酸的再组合;可提高氨基酸,尤其是必需的氨基酸蛋氨酸在体内的利用率。
L抗坏血酸钠:医药上用于补充维生素C,添加于食品和饮料中可用于抗氧化,能有效防止食品和饮料变色,变味。
醋酸视黄酯::即醋酸维生素A,能够维持人体正常代谢,能够维持细胞膜的稳定和发育、维持生殖系统的正常功能。
D泛酸钙:用于医药、食品及饲料添加剂,是辅酶A的成分,参与碳水化合物、脂肪和蛋白质的代谢作用,临床用于治疗维生素B缺乏症,周围神经炎,手术后肠绞痛,参与蛋白质、脂肪、糖在体内的新陈代谢。
dl-α-生育酚:维生素E的水解产物,是最主要的抗氧化剂之一。
胆钙化醇:又称为维生素D3或胆钙化固醇,是维生素D的一种,是一种脂溶性维生素,也被看作是一种作用于钙、磷代谢的激素前体。
植物甲萘醌:又称为维生素K1,属于一种多环芳香酮,是一种脂溶性维生素,对空气和潮湿稳定,但在阳光下会被分解,属维生素类药物,主要用于各种维生素K缺乏引起的出血性疾病的治疗。
核黄素:又叫维生素B2,为体内黄酶类辅基的组成部分(黄酶在生物氧化还原中发挥递氢作用),当缺乏时,就影响机体的生物氧化,使代谢发生障碍。其病变多表现为口、眼和外生殖器部位的炎症,如口角炎、唇炎、舌炎、眼结膜炎和阴囊炎等。
烟酰胺:烟酰胺是维生素B族中的一员,维生素B3,烟酸可以在活体内被转变为烟酰胺。
D-生物素:又称维生素H、辅酶R,是水溶性维生素,也属于维生素B族、B7,它是合成维生素C的必要物质,是脂肪和蛋白质正常代谢不可或缺的物质,是一种维持人体自然生长、发育和正常人体机能健康必要的营养素。
叶酸:维生素B复合体之一,有促进骨髓中幼细胞成熟的作用,人类如缺乏叶酸可引起巨红细胞性贫血以及白细胞减少症,对孕妇尤其重要。
烟酸:烟酸也称作维生素B3,烟酸又名尼克酸、抗癞皮病因子,在人体内还包括其衍生物烟酰胺或尼克酰胺,它是人体必需的13种维生素之一,是一种水溶性维生素。
泛酸:也称作维生素B5、遍多酸,无臭,味微苦,因其性质偏酸性并广泛存于多种食物中,故而得名。一般公认泛酸与头发、皮肤的营养状态密切相关,当头发缺乏光泽或变得较稀疏时,多补充泛酸可见其效;制造抗体也是泛酸的作用之一,能帮助人体抵抗传染病,缓和多种抗生素副作用及毒性,减轻过敏症状,泛酸缺乏易引起血液及皮肤异常,产生低血糖等症
盐酸硫胺素:是硫胺的盐酸盐,是维生素B1的一种存在形式,营养增补剂,维生素B1在体内参与糖类的中间代谢。
盐酸吡哆醇:又叫维生素B6,白色或类白色的结晶或结晶性粉末,无臭,味酸苦,维生素强化剂,本品是机体内很多酶如转氨基酶、脱羧酶、消旋酶、脱氢酶、合成酶和羟化酶等的辅酶,且可帮助糖类和蛋白质的分解、利用,缺乏时有类似烟酸的缺乏症,此外维生素B6还参与色氨酸将烟酸转化为5-羟色胺的反应。并可刺激白细胞的生长,是形成血红蛋白所需要的物质。
钴胺素:维生素B12,作为甲基转移酶的辅因子,参与蛋氨酸、胸腺嘧啶等的合成,如使甲基四氢叶酸转变为四氢叶酸而将甲基转移给甲基受体,使甲基受体成为甲基衍生物。
磷酸氢钙:作强化剂(补充钙)和膨松剂,也可作为品质改良剂,用于发酵面制品,按生产需要适量使用,作为食品饲料添加剂,以补充禽畜饲料中的磷、钙元素。
磷酸三钙:磷酸三钙是一种安全的营养强化剂,主要添加在食品中强化钙的摄入,也可用于预防或治疗钙缺乏的症状。同时磷酸三钙还可作为食品中的抗结剂、PH值调节剂,缓冲剂等。
氯化镁:可做食品添加剂、蛋白凝固剂、融雪剂、冷冻剂、防尘剂、耐火材料等。
焦磷酸铁:用于食品工业作营养增补剂(铁质强化剂),用于强化奶粉,婴儿食品及其他一般食品。
氧化锌:氧化锌作为添加剂在多种材料和产品有应用,包括塑料、陶瓷、玻璃、水泥、润滑剂、油漆、软膏、粘合剂、填隙材料、颜料、食品(补锌剂)、电池、铁氧体材料、阻燃材料和医用急救绷带等。
氯化钠:氯化钠是人所不可缺少的,钠离子和氯离子的生理功能主要有:维持细胞外液的渗透压,参与体内酸碱平衡的调节,氯离子在体内参与胃酸的生成,此外,氯化钠在维持神经和肌肉的正常兴奋性上也有作用。
氯化钾:食品行业中,可用作食盐代用品应用于农产、水产、畜产、发酵、调味、罐头、方便食品等,制作低钠产品,以降低钠含量过高对机体的不良影响。
碘化钾:在医药上用于防治地方性甲状腺肿,促进眼玻璃体浑浊的吸收及祛痰,用作照相感光乳化剂、食品添加剂、碘及某些难溶金属碘化物的助溶剂。
硫酸锰:是合成脂肪酸的作物需要的微量元素。
亚硒酸钠:硒是谷胱苷肽过氧化酶的组成部分,通过氧化作用维持细胞膜的功能,提高蛋白质的脂类性质的内源性抗氧化剂的产量,参与能量的转化,影响代谢,对脂肪的乳化、吸收和多种维生素的吸收起着极其重要的作用,同时还参与与辅酶A、辅酶Q的合成,影响其他生物酶系统的功能,对氨基酸的代谢、蛋白质的合成、糖类代谢、生物氧化都有影响。
本发明的有益效果为:
(1)、本发明提供的可缓解视觉和体力疲劳的功能性饮料同时利用各原料的有效成分,使其相辅相成,大大提高该饮料缓解体力疲劳和视力疲劳的功效,同时兼具优异的保健性能。大大提高了各组分的分散性能,且有效减少其中营养成分的流失,使制备得的饮料成品稳定性高,有利于大规模工业化生产。
(2)、本发明提供的可缓解视觉和体力疲劳的功能性饮料科学地把上述各种功效成分融入产品之中,这些成分相互配合,协同作用,能够促进人体新陈代谢,吸收与分解糖分,迅速补充大量的能量物质,并调节神经系统功能,从而取得提神醒脑、补充体力、抗疲劳的卓越功效。因此,人在生理性疲劳之时,体内能量物质缺乏,能量代谢不足或存在障碍,饮用该功能饮料,可以充分补充能量,快速消除疲劳,振奋精神,提高工作效率与生活质量。
(3)、本发明提供的可缓解视觉和体力疲劳的功能性饮料在大量运动或者重体力劳动后饮用,或者次日比赛睡眠前饮用,能够有效缓解疲劳,提高睡眠质量;健脾开胃,帮助消化;同时能够提高心脏供血功能;各个原料相互协同作用,促进体力恢复。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是根据本发明实施例的一种可缓解视觉和体力疲劳的功能性饮料的制备方法流程图。
具体实施方式
为进一步说明各实施例,本发明提供有附图,这些附图为本发明揭露内容的一部分,其主要用以说明实施例,并可配合说明书的相关描述来解释实施例的运作原理,配合参考这些内容,本领域普通技术人员应能理解其他可能的实施方式以及本发明的优点,图中的组件并未按比例绘制,而类似的组件符号通常用来表示类似的组件。
根据本发明的实施例,提供了一种可缓解视觉和体力疲劳的功能性饮料。
根据本发明实施例的可缓解视觉和体力疲劳的功能性饮料,该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物7-15份、薄荷提取物3-4份、山茱萸提取物1-5份、茶树紫芽花青素10-17份、乳糖75-125份、浓缩乳清蛋白32-55份、咖啡因0.08-0.12份、低聚半乳糖14-26份、玛咖0.2-1.5份、肌醇19-20份、亚油酸2.8-2.86份、柠檬酸0.1-0.5份、香精0.1-0.2份、α-亚麻酸0.38-0.39份、柠檬酸钠0.1-0.3份、苯甲酸钠0.1-0.3份、水解酪蛋白17.5-18.5份、柠檬黄0.1-0.2份、二十二碳六烯酸10-30份、柠檬酸锌0.04-0.05份、酪蛋白磷酸肽2-3份、卵磷脂25-35份、β-环状糊精0.01-0.02份、调节剂0.3-0.56份、抗氧化剂0.25-0.58份、氨基酸4-7.2份、核苷酸0.25-0.4份、维生素组合物1.562-3.155份、矿物质0.32-0.485份和水1500-4500份。
其中,所述调节剂包括以下原料组份:三聚磷酸钠0.05-0.08份、一水柠檬酸0.2-0.4份和藻酸丙二醇酯0.05-0.08份。
所述抗氧化剂包括以下原料组份:叶黄素0.05-0.25份、D-异抗坏血酸钠0.15-0.22份、超氧化物歧化酶0.02-0.04份、过氧化氢酶0.01-0.03份和丙酮酸0.02-0.04份。
所述氨基酸包括以下原料组份:牛磺酸1-1.2份、肌酸0.4-1.2份、亮氨酸0.4-0.8份、甘氨酸0.3-0.6份、左旋肉碱0.4-0.8份、酪氨酸0.2-0.4份、赖氨酸0.6-0.8份、天冬氨酸0.3-0.6份、茶氨酸0.2-0.4份和谷氨酰胺0.2-0.4份。
所述核苷酸包括以下原料组份:5’单磷酸腺苷0.05-0.08份、5’肌苷酸二钠0.05-0.08份、5’鸟苷酸二钠0.05-0.08份、5’尿苷酸二钠0.05-0.08份和5’胞苷酸二钠0.05-0.08份。
所述维生素组合物包括以下原料组份:氯化胆碱0.015-0.025份、L抗坏血酸钠0.055-0.085份、醋酸视黄酯0.015-0.025份、D泛酸钙0.025-0.035份、dl-α-生育酚0.025-0.045份、胆钙化醇0.035-0.045份、植物甲萘醌0.025-0.045份和B族组合物1.367-2.85份。
所述B族组合物包括以下原料组份:核黄素0.065-0.095份、烟酰胺0.025-0.085份、D-生物素0.012-0.025份、叶酸0.015-0.025份、烟酸0.045-0.065份、泛酸1.1-2.4份、盐酸硫胺素0.045-0.065份、盐酸吡哆醇0.035-0.045份和钴胺素0.025-0.045份。
所述矿物质包括以下原料组份:磷酸氢钙0.02-0.025份、磷酸三钙0.02-0.03份、氯化镁0.06-0.08份、焦磷酸铁0.065-0.095份、氧化锌0.035-0.065份、氯化钠0.015-0.025份、氯化钾0.045-0.065份、碘化钾0.04-0.06份、硫酸锰0.01-0.02份和亚硒酸钠0.01-0.02份。
为了更清楚的理解本发明的上述技术方案,以下通过具体实例对本发明的上述方案进行详细说明。
实施例一
一种可缓解视觉和体力疲劳的功能性饮料,该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物7g、薄荷提取物3g、山茱萸提取物1g、茶树紫芽花青素10g、乳糖75g、浓缩乳清蛋白32g、咖啡因0.08g、低聚半乳糖14g、玛咖0.2g、肌醇19g、亚油酸2.8g、柠檬酸0.1g、香精0.1g、α-亚麻酸0.3g、柠檬酸钠0.1g、苯甲酸钠0.1g、水解酪蛋白17.5g、柠檬黄0.1g、二十二碳六烯酸10g、柠檬酸锌0.04g、酪蛋白磷酸肽2g、卵磷脂25g、β-环状糊精0.01g、调节剂0.3g、抗氧化剂0.25g、氨基酸4g、核苷酸0.25g、维生素组合物1.562g、矿物质0.32g和水1500g。
其中,所述调节剂包括以下原料组份:三聚磷酸钠0.05g、一水柠檬酸0.2g和藻酸丙二醇酯0.05g。
所述抗氧化剂包括以下原料组份:叶黄素0.05g、D-异抗坏血酸钠0.15g、超氧化物歧化酶0.02g、过氧化氢酶0.01g和丙酮酸0.02g。
所述氨基酸包括以下原料组份:牛磺酸1g、肌酸0.4g、亮氨酸0.4g、甘氨酸0.3g、左旋肉碱0.4g、酪氨酸0.2g、赖氨酸0.6g、天冬氨酸0.3g、茶氨酸0.2g和谷氨酰胺0.2g。
所述核苷酸包括以下原料组份:5’单磷酸腺苷0.05g、5’肌苷酸二钠0.05g、5’鸟苷酸二钠0.05g、5’尿苷酸二钠0.05g和5’胞苷酸二钠0.05g。
所述维生素组合物包括以下原料组份:氯化胆碱0.015g、L抗坏血酸钠0.055g、醋酸视黄酯0.015g、D泛酸钙0.025g、dl-α-生育酚0.025g、胆钙化醇0.035g、植物甲萘醌0.025g和B族组合物1.367g。
所述B族组合物包括以下原料组份:核黄素0.065g、烟酰胺0.025g、D-生物素0.012g、叶酸0.015g、烟酸0.045g、泛酸1.1g、盐酸硫胺素0.045g、盐酸吡哆醇0.035g和钴胺素0.025g。
所述矿物质包括以下原料组份:磷酸氢钙0.02g、磷酸三钙0.02g、氯化镁0.06g、焦磷酸铁0.065g、氧化锌0.035g、氯化钠0.015g、氯化钾0.045g、碘化钾0.04g、硫酸锰0.01g和亚硒酸钠0.01g。
该可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
通过预先配置的低频共振仪对所述水进行处理备用;
按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
将制得的所述功能饮料成品密封灌装。
实施例二
一种可缓解视觉和体力疲劳的功能性饮料,该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物11g、薄荷提取物3.5g、山茱萸提取物3g、茶树紫芽花青素14g、乳糖100g、浓缩乳清蛋白46g、咖啡因0.1g、低聚半乳糖19g、玛咖0.8g、肌醇19.5g、亚油酸2.83g、柠檬酸0.3g、香精0.15g、α-亚麻酸0.385g、柠檬酸钠0.2g、苯甲酸钠0.2g、水解酪蛋白18g、柠檬黄0.15g、二十二碳六烯酸20g、柠檬酸锌0.045g、酪蛋白磷酸肽2.5g、卵磷脂30g、β-环状糊精0.015g、调节剂0.43g、抗氧化剂0.41g、氨基酸5.6g、核苷酸0.325g、维生素组合物2.303g、矿物质0.398g和水3000g。
其中,所述调节剂包括以下原料组份:三聚磷酸钠0.065g、一水柠檬酸0.3g和藻酸丙二醇酯0.065g。
所述抗氧化剂包括以下原料组份:叶黄素0.15g、D-异抗坏血酸钠0.18g、超氧化物歧化酶0.03g、过氧化氢酶0.02g和丙酮酸0.03g。
所述氨基酸包括以下原料组份:牛磺酸1.1g、肌酸0.8g、亮氨酸0.6g、甘氨酸0.5g、左旋肉碱0.6g、酪氨酸0.3g、赖氨酸0.7g、天冬氨酸0.4g、茶氨酸0.3g和谷氨酰胺0.3g。
所述核苷酸包括以下原料组份:5’单磷酸腺苷0.065g、5’肌苷酸二钠0.065g、5’鸟苷酸二钠0.065g、5’尿苷酸二钠0.065g和5’胞苷酸二钠0.065g。
所述维生素组合物包括以下原料组份:氯化胆碱0.02g、L抗坏血酸钠0.07g、醋酸视黄酯0.02g、D泛酸钙0.03g、dl-α-生育酚0.035g、胆钙化醇0.04g、植物甲萘醌0.035g和B族组合物2.053g。
所述B族组合物包括以下原料组份:核黄素0.08g、烟酰胺0.05g、D-生物素0.018g、叶酸0.02g、烟酸0.055g、泛酸1.7g、盐酸硫胺素0.055g、盐酸吡哆醇0.04g和钴胺素0.035g。
所述矿物质包括以下原料组份:磷酸氢钙0.023g、磷酸三钙0.025g、氯化镁0.07g、焦磷酸铁0.08g、氧化锌0.05g、氯化钠0.02g、氯化钾0.05g、碘化钾0.05g、硫酸锰0.015g和亚硒酸钠0.015g。
该可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
通过预先配置的低频共振仪对所述水进行处理备用;
按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
将制得的所述功能饮料成品密封灌装。
实施例三
一种可缓解视觉和体力疲劳的功能性饮料,该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物15g、薄荷提取物4g、山茱萸提取物5g、茶树紫芽花青素17g、乳糖125g、浓缩乳清蛋白55g、咖啡因0.12g、低聚半乳糖26g、玛咖1.5g、肌醇20g、亚油酸2.86g、柠檬酸0.5g、香精0.2g、α-亚麻酸0.39g、柠檬酸钠0.3g、苯甲酸钠0.3g、水解酪蛋白18.5g、柠檬黄0.2g、二十二碳六烯酸30g、柠檬酸锌0.05g、酪蛋白磷酸肽3g、卵磷脂35g、β-环状糊精0.02g、调节剂0.56g、抗氧化剂0.58g、氨基酸7.2g、核苷酸0.4g、维生素组合物3.155g、矿物质0.485g和水4500g。
其中,所述调节剂包括以下原料组份:三聚磷酸钠0.08g、一水柠檬酸0.4g和藻酸丙二醇酯0.08g。
所述抗氧化剂包括以下原料组份:叶黄素0.25g、D-异抗坏血酸钠0.22g、超氧化物歧化酶0.04g、过氧化氢酶0.03g和丙酮酸0.04g。
所述氨基酸包括以下原料组份:牛磺酸1.2g、肌酸1.2g、亮氨酸0.8g、甘氨酸0.6g、左旋肉碱0.8g、酪氨酸0.4g、赖氨酸0.8g、天冬氨酸0.6g、茶氨酸0.4g和谷氨酰胺0.4g。
所述核苷酸包括以下原料组份:5’单磷酸腺苷0.08g、5’肌苷酸二钠0.08g、5’鸟苷酸二钠0.08g、5’尿苷酸二钠0.08g和5’胞苷酸二钠0.08g。
所述维生素组合物包括以下原料组份:氯化胆碱0.025g、L抗坏血酸钠0.085g、醋酸视黄酯0.025g、D泛酸钙0.035g、dl-α-生育酚0.045g、胆钙化醇0.045g、植物甲萘醌0.045g和B族组合物2.85g。
所述B族组合物包括以下原料组份:核黄素0.095g、烟酰胺-0.085g、D-生物素0.025g、叶酸0.025g、烟酸0.065g、泛酸2.4g、盐酸硫胺素0.065g、盐酸吡哆醇0.045g和钴胺素0.045g。
所述矿物质包括以下原料组份:磷酸氢钙0.025g、磷酸三钙0.03g、氯化镁0.08g、焦磷酸铁0.095g、氧化锌0.065g、氯化钠0.025g、氯化钾0.065g、碘化钾0.06g、硫酸锰0.02g和亚硒酸钠0.02g。
该可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
通过预先配置的低频共振仪对所述水进行处理备用;
按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
将制得的所述功能饮料成品密封灌装。
为了方便理解本发明的上述技术方案,以下结合附图对本发明的上述方案的流程进行详细说明,具体如下:
如图1所示,在实际生产过程中,该可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
步骤S101,根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
步骤S103,对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
步骤S105,通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
步骤S107,通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
步骤S109,通过预先配置的低频共振仪对所述水进行处理备用;
步骤S111,按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
步骤S113,将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
步骤S115,通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
步骤S117,将制得的所述功能饮料成品密封灌装。
在一个实施例中,所述灭菌处理采用高温杀菌,其温度为100-110℃,杀菌时间为30-35分种。
为了方便理解本发明的上述技术方案,以下结合实验数据对本发明的上述方案的进行详细说明,具体如下:
试验报告:
1、睡眠质量实验:
实验对象:运动员20名,男性。实验工具:匹兹堡睡眠质量指数(PSQI),PSQI的总分范围为0-21分,得分越高,表示睡眠质量越差。试验方法:20名运动员分成两组,每组10份分别为实验组和对照组。1-5日,不进行任何训练,6-15日,每天安排相同高强度训练,实验组训练后和睡前分别饮用本发明饮料500g,对照组不饮用任何饮料。
表1,实验组和对照组睡眠质量表
对照组M±SD | 实验组M±SD | |
睡眠总分 | 9.52±2.16 | 6.95±2.22 |
自觉睡质 | 1.36±0.27 | 1.30±0.35 |
入睡时间 | 1.92±0.51 | 1.28±0.52 |
睡眠时间 | 1.04±0.41 | 0.86±0.26 |
睡眠效率 | 1.11±0.23 | 1.02±0.30 |
睡眠障碍 | 1.27±0.26 | 1.03±0.20 |
催眠药物 | 0.15±0.32 | 0.10±0.40 |
日功障碍 | 2.16±0.31 | 2.03±0.33 |
实验结论:如表1所示,实验组睡眠质量明显优于对照组睡眠质量。
2、急性毒性试验
采用霍恩氏法,选取健康小白鼠,适应环境5天,服用前禁食16小时,不禁水,在正式试验前以20倍剂量灌胃小鼠进行预试验,小鼠无异常,遂选用体重JJ2sg左右的小鼠40只(雌雄各半),随机分成5组,分别以人体剂量的5倍、10倍、20倍、40倍及80倍为小鼠受试剂量进行试驻,分别将上述剂量一次性经口灌胃,灌胃体积为0.2mU10g-bw。灌胃后连续观察1周左右,记录中毒表现及死亡情况。
表2饮料中小鼠急性毒性试验结果
剂量组 | 小鼠数量(只) | 中毒症状 | 死亡情况 |
5倍 | 8 | 无中毒 | 无死亡 |
10倍 | 8 | 无中毒 | 无死亡 |
20倍 | 8 | 无中毒 | 无死亡 |
40倍 | 8 | 无中毒 | 无死亡 |
80倍 | 8 | 无中毒 | 无死亡 |
3、遗传毒性试验
取体重2sg左右的小鼠40只(雌雄各半),饮料中叶黄素浓度为人体摄入量的10、50及100倍作为低剂量组、中剂量组和高剂量组进行试验,另外还设置了阴性对照组(采用蒸馏水)和阳性对照组(采用环磷酰胺,40mg/kg-bw)。每天灌胃1次,连续2天,末次灌胃6小时后取胸骨制作标本,进行阅片。
表3饮料对小鼠骨髓微核发生率的影响
由表3可以看出,试验组动物在各试验剂量下,嗜多染红细胞(PCE)微核出现率、PCE/RBC与阴性对照组的差异均无显著性,而阳性对照组显示强烈的致突变作用,试验说明该饮料无致突变作用。
4、血液学指标
采集血清时,将一部分血液盛于加抗凝剂的玻璃管中,另一部分置于无抗凝剂玻璃管中待刚。取抗凝血于血液分析仪中测定试验末期的常规血液学指标:血红蛋白、红细胞、白细胞,结果如下:
表4大鼠血液学指标测定结果(X±S,g)
由表4可以看出,功能饮料的高、中、低三组小鼠血液学指标与对照组相比均无显著性差异(P>0.05),表明各剂量纽对小鼠的血液学指标无异常改变。因为血液中的红细胞、白细胞和血红蛋白与血浆是组成机体新陈代谢及功能调节所不可或缺的血液循环系统,血液中的任何指标成分发生病理变化,都会影响到全身的组织器官。冈此可以通过对大鼠血液中的红细胞,白细胞和血红蛋白的三项指标进行分析,能够了解机体的健康状况。上述实验结果测得血液学指标正常,说明该饮料未引起火鼠组织性或器官性的变化。
综上所述,借助于本发明的上述技术方案,本发明提供的可缓解视觉和体力疲劳的功能性饮料同时利用各原料的有效成分,使其相辅相成,大大提高该饮料缓解体力疲劳和视力疲劳的功效,同时兼具优异的保健性能。大大提高了各组分的分散性能,且有效减少其中营养成分的流失,使制备得的饮料成品稳定性高,有利于大规模工业化生产。本发明提供的可缓解视觉和体力疲劳的功能性饮料科学地把上述各种功效成分融入产品之中,这些成分相互配合,协同作用,能够促进人体新陈代谢,吸收与分解糖分,迅速补充大量的能量物质,并调节神经系统功能,从而取得提神醒脑、补充体力、抗疲劳的卓越功效。因此,人在生理性疲劳之时,体内能量物质缺乏,能量代谢不足或存在障碍,饮用该功能饮料,可以充分补充能量,快速消除疲劳,振奋精神,提高工作效率与生活质量。本发明提供的可缓解视觉和体力疲劳的功能性饮料在大量运动或者重体力劳动后饮用,或者次日比赛睡眠前饮用,能够有效缓解疲劳,提高睡眠质量;健脾开胃,帮助消化;同时能够提高心脏供血功能;各个原料相互协同作用,促进体力恢复。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种可缓解视觉和体力疲劳的功能性饮料,其特征在于,该可缓解视觉和体力疲劳的功能性饮料由以下质量份数的原料制成:
枸杞提取物7-15份、薄荷提取物3-4份、山茱萸提取物1-5份、茶树紫芽花青素10-17份、乳糖75-125份、浓缩乳清蛋白32-55份、咖啡因0.08-0.12份、低聚半乳糖14-26份、玛咖0.2-1.5份、肌醇19-20份、亚油酸2.8-2.86份、柠檬酸0.1-0.5份、香精0.1-0.2份、α-亚麻酸0.38-0.39份、柠檬酸钠0.1-0.3份、苯甲酸钠0.1-0.3份、水解酪蛋白17.5-18.5份、柠檬黄0.1-0.2份、二十二碳六烯酸10-30份、柠檬酸锌0.04-0.05份、酪蛋白磷酸肽2-3份、卵磷脂25-35份、β-环状糊精0.01-0.02份、调节剂0.3-0.56份、抗氧化剂0.25-0.58份、氨基酸4-7.2份、核苷酸0.25-0.4份、维生素组合物1.562-3.155份、矿物质0.32-0.485份和水1500-4500份。
2.根据权利要求1所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述调节剂包括以下原料组份:三聚磷酸钠0.05-0.08份、一水柠檬酸0.2-0.4份和藻酸丙二醇酯0.05-0.08份。
3.根据权利要求2所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述抗氧化剂包括以下原料组份:叶黄素0.05-0.25份、D-异抗坏血酸钠0.15-0.22份、超氧化物歧化酶0.02-0.04份、过氧化氢酶0.01-0.03份和丙酮酸0.02-0.04份。
4.根据权利要求3所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述氨基酸包括以下原料组份:牛磺酸1-1.2份、肌酸0.4-1.2份、亮氨酸0.4-0.8份、甘氨酸0.3-0.6份、左旋肉碱0.4-0.8份、酪氨酸0.2-0.4份、赖氨酸0.6-0.8份、天冬氨酸0.3-0.6份、茶氨酸0.2-0.4份和谷氨酰胺0.2-0.4份。
5.根据权利要求4所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述核苷酸包括以下原料组份:5’单磷酸腺苷0.05-0.08份、5’肌苷酸二钠0.05-0.08份、5’鸟苷酸二钠0.05-0.08份、5’尿苷酸二钠0.05-0.08份和5’胞苷酸二钠0.05-0.08份。
6.根据权利要求5所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述维生素组合物包括以下原料组份:氯化胆碱0.015-0.025份、L抗坏血酸钠0.055-0.085份、醋酸视黄酯0.015-0.025份、D泛酸钙0.025-0.035份、dl-α-生育酚0.025-0.045份、胆钙化醇0.035-0.045份、植物甲萘醌0.025-0.045份和B族组合物1.367-2.85份。
7.根据权利要求6所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述B族组合物包括以下原料组份:核黄素0.065-0.095份、烟酰胺0.025-0.085份、D-生物素0.012-0.025份、叶酸0.015-0.025份、烟酸0.045-0.065份、泛酸1.1-2.4份、盐酸硫胺素0.045-0.065份、盐酸吡哆醇0.035-0.045份和钴胺素0.025-0.045份。
8.根据权利要求7所述的可缓解视觉和体力疲劳的功能性饮料,其特征在于,所述矿物质包括以下原料组份:磷酸氢钙0.02-0.025份、磷酸三钙0.02-0.03份、氯化镁0.06-0.08份、焦磷酸铁0.065-0.095份、氧化锌0.035-0.065份、氯化钠0.015-0.025份、氯化钾0.045-0.065份、碘化钾0.04-0.06份、硫酸锰0.01-0.02份和亚硒酸钠0.01-0.02份。
9.一种可缓解视觉和体力疲劳的功能性饮料的制备方法,其特征在于,用于权利要求8所述的可缓解视觉和体力疲劳的功能性饮料的制备,包括以下步骤:
根据上述质量份数,称取所述可缓解视觉和体力疲劳的功能性饮料所需原料,并在称取过程中,将除所述水以外的所有原料注入同一容器中,促使原料进行混合,形成初步混合物;
对所述初步混合物进行连续搅拌,使所述原料充分混合,形成充分混合物;
通过预先配置的筛选机对所述充分混合物进行过筛筛选,促使所述充分混合物的状态为粉状混合物;
通过预先配置的金属分离器,对过筛筛选后的充分混合物进行二次筛选,形成超细粉状混合物,并将得到的超细粉状混合物放入贮藏箱中进行存储备用;
通过预先配置的低频共振仪对所述水进行处理备用;
按预先预置配比将所述超细粉状混合物与所述低频共振水进行充分混合、搅拌均匀制得初步混合液;
将所述初步混合液依次进行高速离心分离、均质、灭菌处理,制得均质混合液;
通过预先配置的低频共振仪将所述均质混合液进行处理得到功能饮料;
将制得的所述功能饮料成品密封灌装。
10.根据权利要求9所述的可缓解视觉和体力疲劳的功能性饮料的制备方法,其特征在于,所述灭菌处理采用高温杀菌,其温度为100-110℃,杀菌时间为30-35分种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811554191.0A CN109527313A (zh) | 2018-12-18 | 2018-12-18 | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811554191.0A CN109527313A (zh) | 2018-12-18 | 2018-12-18 | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109527313A true CN109527313A (zh) | 2019-03-29 |
Family
ID=65853615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811554191.0A Pending CN109527313A (zh) | 2018-12-18 | 2018-12-18 | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109527313A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021041293A1 (en) * | 2019-08-23 | 2021-03-04 | The Coca-Cola Company | Stable creatine beverages |
CN114096165A (zh) * | 2020-04-10 | 2022-02-25 | 上海利统生化制品有限公司 | 一种缓解视疲劳的可食用组合物 |
CN114451506A (zh) * | 2022-02-22 | 2022-05-10 | 韦东 | 一种功能性的复合饮品配方及其生产工艺 |
CN117337988A (zh) * | 2023-11-30 | 2024-01-05 | 吉林浩泰健康产业发展股份有限公司 | 一种电解质固体饮料及其制备方法 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036515A (zh) * | 2006-03-13 | 2007-09-19 | 中食肽灵(北京)生物科技有限公司 | 一种体力恢复保健食品及其制备方法 |
CN101803633A (zh) * | 2010-04-23 | 2010-08-18 | 杭州宏胜饮料集团有限公司 | 缓解视疲劳保健乳饮料及其制备方法 |
CN102150724A (zh) * | 2011-03-30 | 2011-08-17 | 姜天安 | 一种提神缓解体力和视觉疲劳的功能性混合物及其应用 |
CN102763878A (zh) * | 2012-07-25 | 2012-11-07 | 北京中科健宇生物科技有限公司 | 一种玛咖功能性保健饮料及其制备方法 |
CN102960810A (zh) * | 2012-12-05 | 2013-03-13 | 上海普维健康食品有限公司 | 玛咖饮料 |
CN103211259A (zh) * | 2013-04-22 | 2013-07-24 | 河南省淼雨饮品股份有限公司 | 一种抗疲劳维生素保健饮料及其制备方法 |
CN104223119A (zh) * | 2014-07-30 | 2014-12-24 | 理想科技集团有限公司 | 用于缓解体力疲劳的玛咖蛋白营养补充剂及其制备方法 |
CN107252114A (zh) * | 2017-07-01 | 2017-10-17 | 马南行 | 一种增强免疫力抗衰老的组合物及其制备方法 |
CN107439890A (zh) * | 2017-08-22 | 2017-12-08 | 王海军 | 一种抗疲劳固体饮料及其制备方法 |
CN107811176A (zh) * | 2017-11-07 | 2018-03-20 | 张永刚 | 马基莓健康功能饮料及制备方法 |
CN107821602A (zh) * | 2017-10-30 | 2018-03-23 | 诺和生物技术(天津)有限公司 | 一种适宜肌肉衰减人群食用的营养配方粉及其制备方法 |
CN108174921A (zh) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | 一种有机婴儿配方奶粉 |
CN108450962A (zh) * | 2018-02-27 | 2018-08-28 | 湖北圣峰药业有限公司 | 一种用于女士保健的固体饮料及其制备方法 |
CN108606199A (zh) * | 2018-03-27 | 2018-10-02 | 佛山市体视能饮料有限公司 | 一种可缓解体力和视力疲劳的功能性饮料及其制备方法 |
CN108651634A (zh) * | 2018-04-24 | 2018-10-16 | 宁波米拉山国际贸易有限公司 | 一种适合0到6个月婴儿的配方奶粉及其制备方法 |
-
2018
- 2018-12-18 CN CN201811554191.0A patent/CN109527313A/zh active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036515A (zh) * | 2006-03-13 | 2007-09-19 | 中食肽灵(北京)生物科技有限公司 | 一种体力恢复保健食品及其制备方法 |
CN101803633A (zh) * | 2010-04-23 | 2010-08-18 | 杭州宏胜饮料集团有限公司 | 缓解视疲劳保健乳饮料及其制备方法 |
CN102150724A (zh) * | 2011-03-30 | 2011-08-17 | 姜天安 | 一种提神缓解体力和视觉疲劳的功能性混合物及其应用 |
CN102763878A (zh) * | 2012-07-25 | 2012-11-07 | 北京中科健宇生物科技有限公司 | 一种玛咖功能性保健饮料及其制备方法 |
CN102960810A (zh) * | 2012-12-05 | 2013-03-13 | 上海普维健康食品有限公司 | 玛咖饮料 |
CN103211259A (zh) * | 2013-04-22 | 2013-07-24 | 河南省淼雨饮品股份有限公司 | 一种抗疲劳维生素保健饮料及其制备方法 |
CN104223119A (zh) * | 2014-07-30 | 2014-12-24 | 理想科技集团有限公司 | 用于缓解体力疲劳的玛咖蛋白营养补充剂及其制备方法 |
CN107252114A (zh) * | 2017-07-01 | 2017-10-17 | 马南行 | 一种增强免疫力抗衰老的组合物及其制备方法 |
CN107439890A (zh) * | 2017-08-22 | 2017-12-08 | 王海军 | 一种抗疲劳固体饮料及其制备方法 |
CN107821602A (zh) * | 2017-10-30 | 2018-03-23 | 诺和生物技术(天津)有限公司 | 一种适宜肌肉衰减人群食用的营养配方粉及其制备方法 |
CN107811176A (zh) * | 2017-11-07 | 2018-03-20 | 张永刚 | 马基莓健康功能饮料及制备方法 |
CN108174921A (zh) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | 一种有机婴儿配方奶粉 |
CN108450962A (zh) * | 2018-02-27 | 2018-08-28 | 湖北圣峰药业有限公司 | 一种用于女士保健的固体饮料及其制备方法 |
CN108606199A (zh) * | 2018-03-27 | 2018-10-02 | 佛山市体视能饮料有限公司 | 一种可缓解体力和视力疲劳的功能性饮料及其制备方法 |
CN108651634A (zh) * | 2018-04-24 | 2018-10-16 | 宁波米拉山国际贸易有限公司 | 一种适合0到6个月婴儿的配方奶粉及其制备方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021041293A1 (en) * | 2019-08-23 | 2021-03-04 | The Coca-Cola Company | Stable creatine beverages |
CN114096165A (zh) * | 2020-04-10 | 2022-02-25 | 上海利统生化制品有限公司 | 一种缓解视疲劳的可食用组合物 |
CN114096165B (zh) * | 2020-04-10 | 2023-09-19 | 上海利统生化制品有限公司 | 一种缓解视疲劳的可食用组合物 |
CN114451506A (zh) * | 2022-02-22 | 2022-05-10 | 韦东 | 一种功能性的复合饮品配方及其生产工艺 |
CN117337988A (zh) * | 2023-11-30 | 2024-01-05 | 吉林浩泰健康产业发展股份有限公司 | 一种电解质固体饮料及其制备方法 |
CN117337988B (zh) * | 2023-11-30 | 2024-03-12 | 吉林浩泰健康产业发展股份有限公司 | 一种电解质固体饮料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2255818B1 (en) | Oral or enteral composition useful for recovery of physical functions | |
CN100355420C (zh) | 富含亮氨酸的营养组合物 | |
CN107495343A (zh) | 一种代餐奶昔及其制备方法 | |
CN103211259B (zh) | 一种抗疲劳维生素保健饮料及其制备方法 | |
CN109527313A (zh) | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 | |
CN104509919A (zh) | 一种功能性营养素饮料 | |
JP2014501530A (ja) | カルシウムベータ−ヒドロキシ−ベータメチルブチレートと共役リノール酸とを含む栄養補助製品 | |
CN108142927A (zh) | 一种用于满足运动控制体重需求的组合物及其制备方法 | |
CN108651998A (zh) | 一种具有缓解疲劳功能的乳清蛋白粉及其制备方法 | |
CN112137095A (zh) | 一种运动营养组合物及其制备方法 | |
CN108077911A (zh) | 一种癫痫患者专用型临床营养配方及其制备方法 | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
CN107048137A (zh) | 一种适用于慢性肾病患者的低磷乳清蛋白粉及其制备方法 | |
CN101842094A (zh) | 含有氨基酸组合物的抗疲劳剂 | |
CN102160664A (zh) | 儿童营养饮料 | |
CN108651634A (zh) | 一种适合0到6个月婴儿的配方奶粉及其制备方法 | |
EP1549158B1 (en) | Infant formula containing nucleotides | |
CN108013299A (zh) | 补充体能饮料 | |
CN108606269A (zh) | 一种运动型营养补充剂及其制备方法 | |
CN106418067A (zh) | 一种补充体力、缓解疲劳的保健饮料 | |
CN110973645A (zh) | 一种具有脑神经营养作用的蛋白粉 | |
CN102579956B (zh) | 一种药物组合物及其应用 | |
JP2017203018A (ja) | 栄養飲料水、動物性・植物性食物の栄養素を体内の細胞に与え、頭皮には混合育毛液を併用した、賦活による育毛法。 | |
CN110584120A (zh) | 骨健康组合物 | |
JP2016506753A (ja) | 食品組成物及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |